Scoliosis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Scoliosis includes a heterogeneous group of conditions with varied presentations, progression, and natural history. The etiology of EOS can be idiopathic or due to various scoliosis-associated syndromes, such as congenital vertebral anomalies or neuromuscular diseases. The incidence of Paediatric Scoliosis (PS) is four times more in Europe when compared with the United States; 1 to 2 cases per 10,000 population, and is more frequent in Asian region countries. Infantile idiopathic scoliosis (IIS) constitutes only 1% of the idiopathic scoliosis population. IIS is more common in males, tends to be left-sided, and 70 to 90% occur in the mid to lower thoracic spine.
·
The incidence of scoliosis is 15% to 28%
amongst children with cerebral palsy, with institutionalized patients, spastic
quadriplegic CP, and children with limited motor function being most commonly
affected.
Thelansis’s “Scoliosis Market Outlook,
Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To
2032" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Scoliosis treatment modalities options for
eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Scoliosis across 8 MM market from the centre of Excellence/ Public/ Private
hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Scoliosis Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment